Neogen (NASDAQ: NEOG) has launched Igenity BCHF, a new genomic test aimed at improving bovine heart health. The test is designed to address the growing concern of Bovine Congestive Heart Failure (BCHF), a condition that poses significant risks to cattle health and productivity. With this development, Neogen seeks to offer a more effective method for identifying and managing genetic predispositions to heart failure in cattle.
“Igenity BCHF is a groundbreaking genomic test that evaluates an animal’s genetic risk for heart failure,” said Dr. Victor Pedrosa, Director of Technical Genomics and Innovation at Neogen. “The test provides a clear indication of the likelihood that an animal will develop BCHF, along with the risk it may pass on to its offspring.”
The Igenity BCHF test assigns a score on a scale from 1 to 10, with 1 indicating the lowest risk and 10 representing the highest risk for BCHF. For each point reduction in score, there is a corresponding 3.5% decrease in the likelihood of the animal developing the condition. For example, animals with a score of 2 have a genetic predisposition for BCHF at just 3.5%, while those with a score of 7 face a 21.2% risk.
A case study conducted in a feedlot setting showed the significant difference in risk between animals with varying scores. Cattle with a lower Igenity score of 2 demonstrated a much lower genetic risk of BCHF compared to those with a higher score of 7, with a 17.7% reduction in the probability of developing the condition.
This new genomic testing tool gives cattle producers an important opportunity to enhance herd health and reduce the long-term risks associated with BCHF.
Related topics:
- Artificial Hearts Show Potential to Regenerate Heart Muscle in Patients with Heart Failure
- New Gene Therapy Shows Promise in Reversing Heart Failure in Animal Model
- Secretome Therapeutics Secures $20.4 Million in Funding to Propel Heart Disease Therapies